SpectraMax i3 Multi-Mode Detection System
See how you can do more with your microplate reader than you ever imagined.
Watch Video
Bioanalysis of Oxytocin
Ultrasensitive Quantification Assay for Oxytocin in Human Plasma Using an LC/MS Microfluidics Platform
Watch Video

Overcoming the disruption dip in the aftermath of M&A

By Roger Humphrey
M&A deals are disrupting the life science industry - and that’s good, mostly. Yet, when a company reshapes its facilities footprint in the wake of a consolidation, cost efficiency can be undermined by the dreaded "disruption dip" in productivity. Here's how to keep your workplaces and laboratories on track.

When two are not enough: lead optimisation beyond matched pairs

By Dr Noel M. O'Boyle, Dr Roger A. Sayle and Dr Matt Segall
Lead optimisation projects progress by making successive enhancements to one or more starting structures. This is a classic multi-objective optimisation procedure.

The increasing impact of precision research models on drug discovery and development

Dr Amar Thyagarajan
Animal models are the standard by which we gain insight into the complex biological processes that underlie human physiology and disease states. Rodent models have been used to understand various aspects of human physiology, disease and treatment outcomes.

The benefits of not competing

By Richard Holland
Pre-competitive collaboration allows a group of competing companies to come together to develop a solution for a problem that they all share, and from which none of them would gain a competitive advantage.

New developments in single cell separation and analysis technologies

By Dr John Comley Drug Discovery
Recent advances of single cell technologies are facilitating the opportunity to discern biological insights within individual cells and providing a means to reveal previously hidden relationships between individual cells within a population.

How neutron science has enabled innovation in drug design and delivery

By Dr Giovanna Fragneto
Meeting global health challenges, from cancer to viral infections, requires a profound understanding of living processes - not just at the level of cells but right down at the molecular level.

The California Institute for Regenerative Medicine’s Human iPSC Initiative

By Dr Thomas J. Novak
In 2012, the California Institute for Regenerative Medicine (CIRM) announced its Human iPSC Initiative, an ambitious effort to generate induced pluripotent stem cell (iPSC) lines from 3,000 donors.

RNA based drugs and vaccines will launch a new era of information driven medicine

By Dr Ingmar Hoerr
Messenger RNA, the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell’s DNA into the proteins essential for maintaining cell function and ensuring an organism's survival, will revolutionise the biopharmaceutical industry.

Introduction to Insights 2015

Robert Jordan, Publisher & Editor in Chief, DDW
Welcome to the third ‘semidecennial’ issue of DDW Insights, a supplement to Drug Discovery World (DDW). Who would have thought, 15 years later, that DDW would still be the driving force in drug discovery and development.

How pharma R&D organisations are adapting to the changing pharma ecosystem

Dr Phil Vickers; Global Head of R&D Shire Pharmaceuticals
Five years ago when considering potential changes to pharmaceutical R&D, I speculated on a number of trends which may become increasingly important.

iPSC-derived cells will improve drug discovery, development and cell therapy

Dr Emile F. Nuwaysir President & COO, Cellular Dynamics International
Over the past several decades the rate of new drug approvals has declined, in part due to the discovery of fewer first-in-class drugs and to the occurrence of costly late-stage failures.

The world of drug discovery five years from now

Dr Roger Brimblecombe; Consultant Editor Drug Discovery World
As Consultant Editor to Drug Discovery World during the 15 years of its existence, I have read some 400+ articles which have proved to be good indicators of trends in the world of drug discovery, be they technical or organisational.

Where will we be in five years?

Dr William N. Hait; Global Head, Research & Development Janssen, Pharmaceutical Companies of Johnson & Johnson
In recent years, the biopharmaceutical industry has made exciting progress. We have furthered our understanding of complex biological processes, harnessed the power of technology to advance drug discovery and development, and generated critical data, both clinical and real-world, that will continue to improve patients’ lives and propel innovation in the life sciences.

The targeted shift in drug discovery and development

Dr Richard Ladd; Senior Director of Pharmaceutical Operations Waters
Throughout my three plus decades working in pharmaceutical research and development, the industry followed a standard and relatively reliable formula for success:

Future-proofing old school pharma with new biology

Dr John Herrmann & Dr Markus Thunecke
It is seems every week one of the major news and analysis publications such as The Economist, The New York Times, FORBES, TIME drills into the hotbutton issue of the perceived disparity between oncology drug pricing and medical-economic value.

Better biological relevancy in drug discovery over the next five years

R. Terry Dunlay; President and CEO IntelliCyt Corporation
The drug discovery industry has been through a tumultuous transformation over the past 10 years. The dust now appears to be settling, and out of it new business models, advances to existing methods and key enabling technologies have emerged.

Pharma today: the challenges ahead – predicting the future

Dr Steve Arlington & Dr Kate Moss
In our 1998 publications Pharma 2005: An Industrial Revolution in R&D and Silicon Rally, we foresaw the challenges ahead for Pharma and predicted the fundamental need for transformation in R&D.

NostraPharmus revived: a future of end and spend or discernible leadership for pharmaceutical companies

Dr Stephen Naylor; Founder, CEO & Chair, MaiHealth Inc
Another five years has passed and the pharmaceutical industry continues to struggle in terms of performance metrics. Today we enquire about his 2010 predictions and request an evaluation of their accuracy.

Powerful new tools and methods for drug discovery

Dr Peter Banks, Scientific Director, BioTek Instruments, Inc.
The Human Genome Project (HGP) was completed in February 2001. The sequencing was conducted by 20 universities and research centres around the globe, took more than a decade and cost almost five billion in 2015 inflation-adjusted US dollars.

Enzo Launches EQ Quencher Dyes for Molecular Biology FRET Applications

Nov 2015
Enzo Life Sciences now offers EQ Quencher Dyes – amine-reactive quencher dyes that can be used for fluorescence resonance energy transfer (FRET) applications.

ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research

September 2015
Molecular Devices launches a new confocal technology at the speed of widefield imaging.

Cayman Chemical and the University of Michigan Issued US Patent for SAM-Screener Epigenetic Methylation Test

September 2015
The United States Patent and Trademark Office has issued a patent to Cayman Chemical and the University of Michigan claiming novel reagents used for screening small-molecule chemical libraries for new drug leads.

Kerafast Partners with the National Cancer Institute (NCI) - Enables Sharing of NCI Research Materials through Kerafast platform

August 2015
Partnership seeks to advance scientific discovery by offering important bioreagents

Proinsulin and Insulin ELISA kits launched

Aug 2015
As a leading manufacturer of ELISAs, Enzo Life Sciences continues to grow its immunoassay portfolio for metabolic research with the introduction of the Proinsulin and Insulin ELISA kits.

BioScale Launches New ViBE Software v3

May 2015
BioScale Launches New ViBE Software v3 For Use On ViBE Platform To Further Increase Productivity And Cost-Efficiency In Drug Development